BGP 15

Drug Profile

BGP 15

Alternative Names: BGP-15

Latest Information Update: 10 Jun 2016

Price : $50

At a glance

  • Originator N-Gene Research Laboratories
  • Developer Allos Therapeutics; N-Gene Research Laboratories; University of Melbourne
  • Class Antihyperglycaemics; Oximes; Piperidines; Small molecules
  • Mechanism of Action HSP70 heat shock protein stimulants; JNK mitogen-activated protein kinase inhibitors; Oxygen radical formation antagonists; Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Duchenne muscular dystrophy

Highest Development Phases

  • Phase II Insulin resistance; Type 2 diabetes mellitus
  • Preclinical Duchenne muscular dystrophy
  • Discontinued Chemoprotection; Reperfusion injury

Most Recent Events

  • 20 Aug 2015 BPG 15 is still in phase-II development for Insulin resistance and Type-2 diabetes mellitus in Hungary and USA
  • 20 Aug 2013 BGP 15 is available for licensing as of 19 Apr 2012. http://www.ngene.us/
  • 31 Jul 2013 N-Gene Research Laboratories terminates a phase II trial in Type-2 diabetes mellitus in Germany, Hungary and USA (NCT01069965)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top